Azizian, Azadeh

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Azizian, A."],["dc.contributor.author","Bernhardt, M."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Koenig, A."],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:20:53Z"],["dc.date.available","2018-11-07T10:20:53Z"],["dc.date.issued","2016"],["dc.format.extent","75"],["dc.identifier.isi","000371353700239"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41971"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Heterogeneity of KRAS Mutation Status in Rectal Cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Langenbeck's Archives of Surgery"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Ghadimi, Michael"],["dc.date.accessioned","2022-09-01T09:51:31Z"],["dc.date.available","2022-09-01T09:51:31Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract\n \n Purpose\n VIPoma belongs to the group of neuroendocrine neoplasms. These tumours are located mostly in the pancreas and produce high levels of vasoactive intestinal peptide (VIP). In most cases, a metastatic state has already been reached at the initial diagnosis, with high levels of VIP leading to a wide spectrum of presenting symptoms. These symptoms include intense diarrhoea and subsequent hypopotassaemia but also cardiac complications, with life-threatening consequences. Treatment options include symptomatic therapy, systemic chemotherapy and targeted therapy, as well as radiation and surgery. Due to the low incidence of VIPoma, there are no prospective studies or evidence-based therapeutic standards to date.\n \n \n Methods\n To evaluate the possible impact of different therapy strategies, we performed literature research using PubMed.\n \n \n Results\n All possible treatment modalities for VIPoma have at least one of two therapy goals: antisecretory effects (symptom control) and antitumoural effects (tumour burden reduction). Symptomatic therapy is the most important in the emergency setting to rehydrate, balance electrolytes and stabilise the patient. Symptomatic therapy is also of great importance perioperatively. Somatostatin analogues play a major role in symptom control, although their efficiency is often limited. Chemotherapy may be effective in reaching stable disease for a certain time period, although its impact on symptom control is limited and often delayed. Among targeted therapy options, the usage of sunitinib appears to be the most effective in terms of symptom control and showing antitumoural effects at the same time. Experience with radiation is still limited; however, local ablative procedures seem to be promising options. Peptide receptor radiotherapy (PRRT) with radiolabelled somatostatin analogues (SSAs, 177Lu-DOTATATE) offers a targeted approach, especially in patients with high somatostatin receptor density. Surgery is the first-line therapy for nonmetastatic VIPoma. Additionally, if the resection of all visible tumour lesions is possible, the surgical approach seems preferable to other strategies in highly symptomatic patients. The role of surgery in very advanced stages where only tumour debulking is possible remains debatable. However, a high rate of immediate symptom control can be achieved by tumour debulking followed by somatostatin therapy, although the impact on survival remains unclear.\n \n \n Conclusion\n Surgery is the only curative option for nonmetastatic VIPoma. Additionally, surgery should be a first-line therapy option for highly symptomatic patients, especially if the resection of all tumour lesions (primary tumour and metastasis) is achievable. In frail patients, other modalities can be used."],["dc.identifier.doi","10.1007/s00423-022-02620-7"],["dc.identifier.pii","2620"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113988"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1435-2451"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Treatment options of metastatic and nonmetastatic VIPoma: a review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Azizian, A."],["dc.contributor.author","Salendo, Junius"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T09:44:05Z"],["dc.date.available","2018-11-07T09:44:05Z"],["dc.date.issued","2014"],["dc.format.extent","7"],["dc.identifier.isi","000332306700021"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34318"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Circulating microRNAs to monitor preoperative CRT in rectal cancer patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1134"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Kensah, George"],["dc.contributor.author","Lara, Angelica Roa"],["dc.contributor.author","Dahlmann, Julia"],["dc.contributor.author","Zweigerdt, Robert"],["dc.contributor.author","Schwanke, Kristin"],["dc.contributor.author","Hegermann, Jan"],["dc.contributor.author","Skvorc, David"],["dc.contributor.author","Gawol, Anke"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Wagner, Stefan"],["dc.contributor.author","Maier, Lars. S."],["dc.contributor.author","Krause, Andreas"],["dc.contributor.author","Draeger, Gerald"],["dc.contributor.author","Ochs, Matthias"],["dc.contributor.author","Haverich, Axel"],["dc.contributor.author","Gruh, Ina"],["dc.contributor.author","Martin, Ulrich"],["dc.date.accessioned","2018-11-07T09:26:20Z"],["dc.date.available","2018-11-07T09:26:20Z"],["dc.date.issued","2013"],["dc.description.abstract","We explored the use of highly purified murine and human pluripotent stem cell (PSC)-derived cardiomyocytes (CMs) to generate functional bioartificial cardiac tissue (BCT) and investigated the role of fibroblasts, ascorbic acid (AA), and mechanical stimuli on tissue formation, maturation, and functionality. Murine and human embryonic/induced PSC-derived CMs were genetically enriched to generate three-dimensional CM aggregates, termed cardiac bodies (CBs). Addressing the critical limitation of major CM loss after single-cell dissociation, non-dissociated CBs were used for BCT generation, which resulted in a structurally and functionally homogenous syncytium. Continuous in situ characterization of BCTs, for 21 days, revealed that three critical factors cooperatively improve BCT formation and function: both (i) addition of fibroblasts and (ii) ascorbic acid supplementation support extracellular matrix remodelling and CB fusion, and (iii) increasing static stretch supports sarcomere alignment and CM coupling. All factors together considerably enhanced the contractility of murine and human BCTs, leading to a so far unparalleled active tension of 4.4 mN/mm(2) in human BCTs using optimized conditions. Finally, advanced protocols were implemented for the generation of human PSC-derived cardiac tissue using a defined animal-free matrix composition. BCT with contractile forces comparable with native myocardium can be generated from enriched, PSC-derived CMs, based on a novel concept of tissue formation from non-dissociated cardiac cell aggregates. In combination with the successful generation of tissue using a defined animal-free matrix, this represents a major step towards clinical applicability of stem cell-based heart tissue for myocardial repair."],["dc.identifier.doi","10.1093/eurheartj/ehs349"],["dc.identifier.isi","000318077500012"],["dc.identifier.pmid","23103664"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30278"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","0195-668X"],["dc.title","Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue in vitro"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e2223225"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","JAMA Network Open"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Rühlmann, Felix"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Mackert, Alma Franziska"],["dc.contributor.author","Engelhardt, Deborah"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Perl, Thorsten"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2022-09-01T09:49:15Z"],["dc.date.available","2022-09-01T09:49:15Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1001/jamanetworkopen.2022.23225"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113381"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","2574-3805"],["dc.title","Incidence, Associated Risk Factors, and Outcomes of Postoperative Arrhythmia After Upper Gastrointestinal Surgery"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","416"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","World Journal of Gastrointestinal Oncology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Gruber, Jens"],["dc.contributor.author","Ghadimi, B Michael"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2020-12-10T18:47:48Z"],["dc.date.available","2020-12-10T18:47:48Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.4251/wjgo.v8.i5.416"],["dc.identifier.issn","1948-5204"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78894"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","MicroRNA in rectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Rühlmann, Felix"],["dc.contributor.author","Krause, Tanja"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Kleiß, Mathias"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2021-04-14T08:27:35Z"],["dc.date.available","2021-04-14T08:27:35Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1038/s41598-020-57930-x"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82341"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","2045-2322"],["dc.title","CA19-9 for detecting recurrence of pancreatic cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","bgac092"],["dc.bibliographiccitation.journal","Carcinogenesis"],["dc.contributor.author","Yang, Shouhui"],["dc.contributor.author","Tang, Wei"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Wang, Limin"],["dc.contributor.author","Cawley, Helen"],["dc.contributor.author","Ohara, Yuuki"],["dc.contributor.author","Valenzuela, Paloma"],["dc.contributor.author","Zhang, Lin"],["dc.contributor.author","Hussain, S Perwez"],["dc.date.accessioned","2022-12-01T08:31:06Z"],["dc.date.available","2022-12-01T08:31:06Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract\n Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy and is largely refractory to available treatments. Identifying key pathways associated with disease aggressiveness and therapeutic resistance may characterize candidate targets to improve patient outcome. We used a strategy of examining the tumors from subset of PDAC patient cohorts with worst survival to understand the underlying mechanisms of aggressive disease progression and to identify candidate molecular targets with potential therapeutic significance. Non-negative matrix factorization (NMF) clustering, using gene expression profile, revealed three patient subsets. A 142-gene signature specific to the subset with the worst patient survival, predicted prognosis and stratified patients with significantly different survival in the test and validation cohorts. Gene-network and pathway analysis of the 142-gene signature revealed dysregulation of Clusterin (CLU) in the most aggressive patient subset in our patient cohort. HNF1B positively regulated CLU, and a lower expression of HNF1B and CLU associated with poor patient survival. Mechanistic and functional analyses revealed that CLU inhibits proliferation, 3D spheroid growth, invasiveness and epithelial-to-mesenchymal transition in pancreatic cancer cell lines. Mechanistically, CLU enhanced proteasomal degradation of EMT-regulator, ZEB1. In addition, orthotopic transplant of CLU-expressing pancreatic cancer cells reduced tumor growth in mice. Furthermore, CLU enhanced sensitivity of pancreatic cancer cells representing aggressive patient subset, to the chemotherapeutic drug gemcitabine. Taken together, HNF1B/CLU axis negatively regulate pancreatic cancer progression and may potentially be useful in designing novel strategies to attenuate disease progression in PDAC patients."],["dc.identifier.doi","10.1093/carcin/bgac092"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118074"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","1460-2180"],["dc.relation.issn","0143-3334"],["dc.title","Dysregulation of HNF1B/Clusterin Axis Enhances Disease Progression in a Highly Aggressive Subset of Pancreatic Cancer Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2618"],["dc.bibliographiccitation.issue","33"],["dc.bibliographiccitation.journal","European heart journal"],["dc.bibliographiccitation.lastpage","2629"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Streckfuss-Boemeke, Katrin"],["dc.contributor.author","Wolf, Frieder"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Stauske, Michael"],["dc.contributor.author","Tiburcy, Malte"],["dc.contributor.author","Wagner, Stefan"],["dc.contributor.author","Huebscher, Daniela"],["dc.contributor.author","Dressel, Ralf"],["dc.contributor.author","Chen, Simin"],["dc.contributor.author","Jende, Jörg"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Lorenz, Verena"],["dc.contributor.author","Schoen, Michael P."],["dc.contributor.author","Maier, Lars S."],["dc.contributor.author","Zimmermann, Wolfram-Hubertus"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Guan, Kaomei"],["dc.date.accessioned","2017-09-07T11:47:10Z"],["dc.date.available","2017-09-07T11:47:10Z"],["dc.date.issued","2013"],["dc.description.abstract","Induced pluripotent stem cells (iPSCs) provide a unique opportunity for the generation of patient-specific cells for use in disease modelling, drug screening, and regenerative medicine. The aim of this study was to compare human-induced pluripotent stem cells (hiPSCs) derived from different somatic cell sources regarding their generation efficiency and cardiac differentiation potential, and functionalities of cardiomyocytes. We generated hiPSCs from hair keratinocytes, bone marrow mesenchymal stem cells (MSCs), and skin fibroblasts by using two different virus systems. We show that MSCs and fibroblasts are more easily reprogrammed than keratinocytes. This corresponds to higher methylation levels of minimal promoter regions of the OCT4 and NANOG genes in keratinocytes than in MSCs and fibroblasts. The success rate and reprogramming efficiency was significantly higher by using the STEMCCA system than the OSNL system. All analysed hiPSCs are pluripotent and show phenotypical characteristics similar to human embryonic stem cells. We studied the cardiac differentiation efficiency of generated hiPSC lines (n 24) and found that MSC-derived hiPSCs exhibited a significantly higher efficiency to spontaneously differentiate into beating cardiomyocytes when compared with keratinocyte-, and fibroblast-derived hiPSCs. There was no significant difference in the functionalities of the cardiomyocytes derived from hiPSCs with different origins, showing the presence of pacemaker-, atrial-, ventricular- and Purkinje-like cardiomyocytes, and exhibiting rhythmic Ca-2 transients and Ca-2 sparks in hiPSC-derived cardiomyocytes. Furthermore, spontaneously and synchronously beating and force-developing engineered heart tissues were generated. Human-induced pluripotent stem cells can be reprogrammed from all three somatic cell types, but with different efficiency. All analysed iPSCs can differentiate into cardiomyocytes, and the functionalities of cardiomyocytes derived from different cell origins are similar. However, MSC-derived hiPSCs revealed a higher cardiac differentiation efficiency than keratinocyte- and fibroblast-derived hiPSCs."],["dc.identifier.doi","10.1093/eurheartj/ehs203"],["dc.identifier.gro","3142288"],["dc.identifier.isi","000324367700013"],["dc.identifier.pmid","22798560"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/6620"],["dc.identifier.url","https://sfb1002.med.uni-goettingen.de/production/literature/publications/61"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation","SFB 1002: Modulatorische Einheiten bei Herzinsuffizienz"],["dc.relation","SFB 1002 | A04: Patienten-spezifische induzierte pluripotente Stammzellen zur funktionellen Untersuchung von Ryanodinrezeptor-Mutationen"],["dc.relation.issn","0195-668X"],["dc.relation.workinggroup","RG Dressel"],["dc.relation.workinggroup","RG Guan (Application of patient-specific induced pluripotent stem cells in disease modelling)"],["dc.relation.workinggroup","RG Hasenfuß (Transition zur Herzinsuffizienz)"],["dc.relation.workinggroup","RG L. Maier (Experimentelle Kardiologie)"],["dc.relation.workinggroup","RG Tiburcy (Stem Cell Disease Modeling)"],["dc.relation.workinggroup","RG Zimmermann (Engineered Human Myocardium)"],["dc.title","Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","E5334"],["dc.bibliographiccitation.issue","23"],["dc.bibliographiccitation.journal","Proceedings of the National Academy of Sciences"],["dc.bibliographiccitation.lastpage","E5343"],["dc.bibliographiccitation.volume","115"],["dc.contributor.author","Max, Klaas E. A."],["dc.contributor.author","Bertram, Karl"],["dc.contributor.author","Akat, Kemal Marc"],["dc.contributor.author","Bogardus, Kimberly A."],["dc.contributor.author","Li, Jenny"],["dc.contributor.author","Morozov, Pavel"],["dc.contributor.author","Ben-Dov, Iddo Z."],["dc.contributor.author","Li, Xin"],["dc.contributor.author","Weiss, Zachary R."],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Sopeyin, Anuoluwapo"],["dc.contributor.author","Diacovo, Thomas G."],["dc.contributor.author","Adamidi, Catherine"],["dc.contributor.author","Williams, Zev"],["dc.contributor.author","Tuschl, Thomas"],["dc.date.accessioned","2020-12-10T18:12:48Z"],["dc.date.available","2020-12-10T18:12:48Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1073/pnas.1714397115"],["dc.identifier.eissn","1091-6490"],["dc.identifier.issn","0027-8424"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74502"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Human plasma and serum extracellular small RNA reference profiles and their clinical utility"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]